Peptio

Peptides in ageing and longevity research

Peptides studied in the context of ageing, where almost all evidence is preclinical and human lifespan data does not exist.

Longevity research has a structural problem: the outcome takes a lifetime to measure. Nothing in this area has human lifespan evidence, and claims rest on surrogate markers or on animal models with much shorter lives.

That is not a reason to ignore the research. It is a reason to be precise about what it shows.

Peptides studied in this area

  • Elamipretide (SS-31)

    SS-31, SS31, MTP-131, Bendavia, Forzinity, RX-31, Ocuvia

    A synthetic mitochondrial tetrapeptide given FDA accelerated approval in 2025 for Barth syndrome only. No trial has tested it against ageing.

    Human RCTApproved for a medical indicationlongevity / safety regulation
  • Epitalon

    Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly, AEDG peptide

    A four-amino-acid peptide studied almost only by one Russian network. No trial with a clinical outcome was found; its lifespan data are from animals.

    Case reportPreclinical onlylongevity / sleep / safety regulation
  • MOTS-c

    MOTs-c, MOTs-C, MOTSc, MOTS-C, Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c

    A 16-amino-acid peptide encoded in mitochondrial DNA. Its metabolic and lifespan data come from mice; no human trial of it has reported results.

    Human obs.Preclinical onlylongevity / safety regulation

Further reading